genOway Logo

genOway

Develops custom genetically modified preclinical models for biopharma and academic research.

ALGEN | PA

Overview

Corporate Details

ISIN(s):
FR0004053510
LEI:
969500HMHUPR3KYXUT19
Country:
France
Address:
31 RUE SAINT JEAN DE DIEU, 69007 LYON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Founded in 1999, genOway is a global biotechnology company specializing in the design and development of genetically modified preclinical models. The company provides a comprehensive portfolio of mouse, rat, and cell line models to bio-pharmaceutical companies, life sciences organizations, and academic researchers. genOway offers both a catalog of validated models and customized model creation services tailored to specific scientific questions. Its core mission is to enhance the predictability of preclinical research, helping to bridge the gap between laboratory findings and clinical success for new therapies. The company leverages deep expertise in biological physiology and a collaborative approach to deliver solutions for clients, including many of the world's top pharmaceutical companies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-27 17:55
Earnings Release
Résultats annuels 2024 - genOway accélère le déploiement de son plan stratégiqu…
French 223.0 KB
2025-01-20 18:00
Earnings Release
Croissance solide de +10% de l'activité en 2024 à 22,1 M EUR
French 194.7 KB
2024-11-04 18:00
Regulatory News Service
Lutte contre l'obésité et les maladies métaboliques : les modèles humanisés de …
French 130.1 KB
2024-09-23 18:00
Earnings Release
Résultats semestriels 2024 conformes avec les objectifs du nouveau plan stratég…
French 207.7 KB
2024-07-18 18:00
Earnings Release
Un 1er semestre 2024 en croissance de +15%, de bon augure en pleine mise en oeu…
French 176.4 KB
2024-07-04 18:00
Business and Financial Review
Bilan semestriel du contrat de liquidité
French 355.0 KB
2024-06-25 17:55
Regulatory News Service
Solide démarrage du développement de la coentreprise genOway Shanghai en Chine
French 198.0 KB
2024-03-28 18:00
Regulatory News Service
Organisation d'une visioconférence destinée aux investisseurs individuels
French 128.0 KB
2024-03-26 17:45
Earnings Release
Résultats annuels 2023 : genOway poursuit sur sa lancée avec une croissance de …
French 219.5 KB
2024-02-09 11:00
Regulatory News Service
genOway fait son entrée au palmarès 2024 des 500 ' Champions de la croissance '
French 129.5 KB
2024-01-22 08:00
Regulatory News Service
genOway participe à la 1ère édition du Retail Day organisée par Euroland Corpor…
French 125.7 KB
2024-01-16 18:05
Board/Management Information
genOway dévoile Route 50+, son nouveau plan stratégique visant à bâtir un leade…
French 198.9 KB
2024-01-16 18:00
Earnings Release
genOway dépasse le seuil des 20 M EUR de chiffre d'affaires en 2023, porté par …
French 176.3 KB
2023-11-22 18:00
Report Publication Announcement
Initiation de la couverture du titre genOway par Euroland Corporate
French 100.2 KB
2023-10-17 18:00
M&A Activity
genOway crée une coentreprise à Shanghai avec pour objectif de devenir le parte…
French 141.9 KB

Automate Your Workflow. Get a real-time feed of all genOway filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for genOway via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-17 N/A Other Sell 1,700 8,160.00 EUR
2023-12-15 N/A Other Sell 5,000 22,000.00 EUR
2023-11-23 N/A Other Sell 500 2,100.00 EUR
2023-10-23 N/A Other Sell 100 390.00 EUR
2023-09-25 N/A Other Buy 5,000 20,000.00 EUR
2023-05-04 N/A Other Buy 60,000 222,000.00 EUR
2023-05-02 N/A Other Sell 20,000 74,000.00 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.